A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women

This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.

Inclusion Criteria:

• Women with postmenopausal osteoporosis

Exclusion Criteria:

• High risk for fractures
• Esophageal abnormalities
• Upper gastrointestinal symptoms that are not relieved with medication
• Metabolic bone disease (example - vitamin D deficiency)
• Medications that would affect the breakdown or build-up of bone